The Assistant Undersecretary of the Ministry of Health for Drug and Food Control Affairs Dr. Abdullah Al-Badr announced the issuance of a ministerial decision to regulate the rules and procedures for pricing medicines in line with the latest Gulf and international standards.
Al-Badr told Kuwait News Agency (KUNA) today, Saturday, that the new decision stipulated not to sell or display any medicine inside pharmacies unless the medicine was registered and priced by the Ministry of Health, and the price in Kuwaiti dinars should be written on it clearly and in a prominent place.
He explained that the decision stipulated that private clinics or hospitals may not handle any medicine in the event that it is not registered and priced by the Ministry of Health, and the price must be separate and clear to the patient with the treatment bill.
He added that, in line with the technological development, the Ministry of Health has committed to publishing drug prices through its official website, coinciding with its publication in the Official Gazette, to facilitate the patient and pharmacies, to ensure that the price list is accessible to everyone.
He stressed the Ministry’s keenness on the need to support local industries and promote local manufacturing for global pharmaceutical companies, which has a direct and positive impact on the advancement of the national economy, keeping pace with the rapid development in pharmaceutical manufacturing, exchanging experiences and information in the field of drug manufacturing and development, and encouraging the attraction of major international drug manufacturers to invest in Kuwait.
Al-Badr stated that one of the articles of the decision stipulated that “the price of the innovative product should not be reduced when any step of manufacturing is transferred locally” due to the intellectual property rights of the patent according to an approved mechanism that maintains the attraction of these expertise and international companies while not compromising the rights of consumers.
Regarding national preparations, he stated that the national generic product (a drug equivalent to a branded medicinal product in terms of drug form, intensity, quality, performance characteristics, and its use) is given a pricing advantage in order to be ahead of the price of non-national generics.
And he indicated that in line with the procedures followed internationally and locally in registering pharmaceutical companies and allocating marketed companies for every product that arrives in the country.
The Ministry has decided to accept price certificates issued by the company that owns the right to market.
Al-Badr said: This procedure is carried out if it is not possible to issue such certificates from the manufacturer of the substance after completing the technical and administrative procedures to approve the price certificate issued by the marketing company in coordination with the company producing the drug.
He pointed out that this procedure comes to facilitate and speed up pricing procedures, which has a great impact on speeding up the registration of materials and their availability in the local market.